Objective To investigate the clinical effect of plasma perfusion (PP) combined with plasma exchange (PE) in the treatment of acute-on-chronic liver failure (ACLF) .Methods A total of 72 patients with ACLF who were admitted to The Second People's Hospital of Lanzhou from January 2014 to December 2015 were enrolled.In addition to internal medication, all the patients were treated with the artificial liver support system (once every 3-4 days based on the patients' conditions, 1-3 times on average for each patient) .According to the difference in therapies, the patients were divided into combination group with 40 patients (PP combined with PE and a total of 107 case times) and control group with 32 patients (PE alone and a total of 85 case times) .Total bilirubin (TBil) , alanine aminotransferase (ALT) , and prothrombin time were recorded before treatment, after surgery, and at 72 hours after surgery.Clinical outcome was evaluated after 4 weeks of treatment.The t-test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups.Results The overall response rate of all patients was 63.89% (46/72) .At 72 hours after surgery, there was a significant difference in the level of ALT between the combination group and the control group (319.54 ± 86.23 U/L vs354.75 ± 100.76 U/L, t=2.60, P<0.05) .Both groups had significant reductions in TBil and ALT after surgery (combination group: t =6.69 and 15.84, P<0.05; control group: t=5.34 and 14.38, P<0.05) and at 72 hours after surgery (combination group: t=3.24 and8.83, P<0.05; control group: t=2.40 and 4.61, P<0.05) .Both groups had significant changes in prothrombin time activity after surgery (t=4.83 and 5.01, both P<0.05) .There were no significant differences in the incidence rates of pruritus and rash between the two groups, while there was a significant difference in the incidence rate of perioral or limb numbness between the two groups (10.28% vs31.76%, χ2=9.11, P<0.05) .Conclusion Both PE combined with PP and PE alone can effectively improve the clinical outcome of ACLF patients with similar response rates; however, PE combined with PP can save the amount of plasma by 40%-50% and reduce the incidence of the adverse effects of PE and has higher safety.Meanwhile, it is in accordance with the social reality of a shortage of blood resources.Therefore, it is a better choice in clinical treatment.
[1]HUEBERT RC, RAKELA J.Cellular therapy for liver disease[J].Mayo Clin Proc, 2014, 89 (3) :414-424.
|
[2]NING GX, LI L, DU J, et al.Research progress of hepatic failure[J].China Med Herald, 2015, 12 (27) :42-46. (in Chinese) 宁更献, 李力, 杜婧, 等.肝衰竭的研究进展[J].中国医药导报, 2015, 12 (27) :42-46.
|
[3]LI LJ.Progress in clinical application of artificial liver support systems[J].Chin J Hepatol, 2005, 13 (11) :844-845. (in Chinese) 李兰娟.人工肝临床应用若干进展[J].中华肝脏病杂志, 2005, 13 (11) :844-845.
|
[4] Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, CMA;Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, CMA.Guideline for diagnosis and treatment of liver failure[J].J Clin Infect Dis, 2012, 5 (6) :321-327. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南 (2012年版) [J].中华临床感染病杂志, 2012, 5 (6) :321-327.
|
[5]LIU YJ, TANG ZX, XIAN YC, et al.Clinical effect of plasma exchange combined with hemoperfusion in treatment of chronic severe hepatitis B[J].Guangdong Med J, 2014, 35 (2) :246-250. (in Chinese) 刘艳娟, 唐振祥, 冼永超, 等.血浆置换联合血液灌流治疗慢性重型乙型肝炎的疗效[J].广东医学, 2014, 35 (2) :246-250.
|
[6]YANG JL, HUANG JR.Application of artificial liver support system intreatment of liver failure[J].J Clin Hepatol, 2015, 31 (9) :1405-1410. (in Chinese) 杨建乐, 黄建荣.人工肝支持系统在肝衰竭治疗中的应用[J].临床肝胆病杂志, 2015, 31 (9) :1405-1410.
|
[7]ZENG YL, CHEN Z, WANG L, et al.Curative effects and influence factors of artificial liver support system combined with antiviral therapy on patients with HBV-related acute-on-chronic liver failure[J/CD].Chin J Liver Dis:Electronic Edition, 2015, 7 (4) :26-30. (in Chinese) 曾义岚, 陈竹, 王丽, 等.人工肝联合抗病毒治疗乙型肝炎相关慢加急性肝功能衰竭患者的疗效及影响因素分析[J/CD].中国肝脏病杂志:电子版, 2015, 7 (4) :26-30.
|
[8]ZHENG HW, LI L, BAI GL, et al.Clinical efficacy and problems of artificial liver support system in treatment of liver failure[J].J Clin Hepatol, 2015, 31 (9) :1411-1414. (in Chinese) 郑欢伟, 李力, 白革兰, 等.人工肝支持系统治疗肝衰竭的临床疗效与问题[J].临床肝胆病杂志, 2015, 31 (9) :1411-1414.
|
[9]ZHANG AM, YOU SL, XIN SJ, et al.Combination therapy of plasma perfusion, plasma exchange, and entecavir in patients with hepatitis B acute-on-chronic liver failure[J].J Clin Hepatol, 2012, 28 (10) :744-747. (in Chinese) 张爱民, 游绍莉, 辛绍杰, 等.血浆吸附灌流联合血浆置换加用恩替卡韦治疗乙型肝炎相关慢加急性肝衰竭的临床疗效[J].临床肝胆病杂志, 2012, 28 (10) :744-747.
|
[10]DUAN XZ, XIN SJ.Artificial liver support as a therapy for liver failure[J].Chin J Hepatol, 2012, 20 (6) :411-413. (in Chinese) 段学章, 辛绍杰.人工肝在肝衰竭治疗中的应用[J].中华肝脏病杂志, 2012, 20 (6) :411-413.
|
[11]ZHANG Y, ZENG WZ, JIANG MD, et al.Effects observation of plasma exchange in treatment of chronic severe hepatitis[J].Chin J Clin Gastroenterol, 2005, 17 (1) :4. (in Chinese) 张勇, 曾维政, 蒋明德, 等.血浆置换治疗慢性重型肝炎临床疗效观察[J].临床消化病杂志, 2005, 17 (1) :4.
|
[12]SHAN Y.Application effect of health education and nursing intervention for artificial liver patients with plasma exchange treatment[J].China Med Herald, 2015, 12 (30) :149-152. (in Chinese) 单颖.人工肝血浆置换患者治疗中健康教育及综合护理干预的应用效果[J].中国医药导报, 2015, 12 (30) :149-152.
|
[13]ZHOU J, WAN H.Relationship between changes in serum cytokine levels after artificial liver therapy and clinical prognosis in patients with liver failure[J].J Clin Hepatol, 2013, 29 (7) :535-537. (in Chinese) 周渐, 万红.肝衰竭患者血浆置换治疗前后细胞因子的变化与预后的关系[J].临床肝胆病杂志, 2013, 29 (7) :535-537.
|
[14]LI LJ, ZHANG YM, LIU XL, et al.Artificial liver support system in China:a review over the last 30 years[J].Ther Apher Dial, 2006, 10 (2) :160-167.
|
[15]YANG JY, CHENG SQ, XIAN YC, et al.Clinical observation of advises reaction of plasma exchange for 137 cases of severe hepatitis[J].China Healthcare Innova, 2009, 4 (13) :38-40. (in Chinese) 杨景毅, 程书权, 冼永超, 等.血浆置换疗法治疗重型肝炎的不良反应137例临床分析[J].中国医疗前沿, 2009, 4 (13) :38-40.
|
[16]PODOLL AS, DEGOLOVINE A, FINKEL KW.Liver support systems:a review[J].ASAIO, 2012, 58 (5) :443-449.
|